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Abstract
Introduction and hypothesis Bladder pain syndrome/interstitial
cystitis (BPS/IC) is identified based on subjective symptoms
which lead to heterogeneous patient populations. Previous
studies using gene expression arrays for BPS/IC with
Hunner’s lesions [European Society for the Study of
Interstitial Cystitis (ESSIC) type 3C], a subtype of the condition
discernible by cystoscopy, have revealed characteristic immune
responses and urothelial abnormalities. This current study
aimed to further characterize this subtype using a gene expres-
sion panel. We hypothesized that B-cell activation with high
levels of urinary antibody concentration would be found.
Methods Cold-cup bladder biopsies, catheterized urine and
blood were collected from 15 BPS/IC ESSIC type 3C pa-
tients, 11 non-inflammatory overactive bladder (OAB) pa-
tients and eight healthy controls. Gene expression in
biopsies was quantified by real-time quantitative
polymerase chain reaction (RT-qPCR), immunohistochem-
istry was performed on bladder tissue and urinary immuno-
globulins G and A were quantified by enzyme-linked
immunosorbent assay. Statistical analyses included the
Kruskal-Wallis test for non-parametric data and post hoc
tests identified differences between groups.
Results High expression of T- and B-cell markers (CTLA4,
CD20, CD79A, IGH@), low expression of urothelial
markers (KRT20, UPK1B, UPK3A), focal lymphoid aggre-
gates in the submucosa and high immunoglobulin concen-
tration in urine were found exclusively in BPS/IC ESSIC
type 3C patients. Results for OAB were in intermediate
ranges between the other two groups and UPK1B even
reached significantly lower expression when compared to
healthy controls.
Conclusions BPS/IC ESSIC type 3C is characterized by a
local adaptive immune response with elevated urinary anti-
body concentrations. Quantification of urinary immuno-
globulin levels could be used for a non-invasive diagnosis
of BPS/IC ESSIC type 3C.
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Introduction
Twenty years ago, the chronic bladder disease “interstitial
cystitis” (IC) was widely regarded as an inflammatory condi-
tion. Published IC research in the early 1990s was based
primarily on biopsy and histological investigations [1, 2].
However, a debate began during this same time about the
need for cystoscopy and biopsy in order to accurately diag-
nose IC [3]. Patients presenting with clinical symptoms such
as pain and urinary frequency, in the absence of any known
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cause, were commonly diagnosed with “IC syndrome” [3].
Due to the subjectivity of this definition, a diverse group of
patients were identified with IC ranging from those with
neuropathic changes to those having a severe inflammation
with macroscopically obvious degeneration of the urothelium.
These broad inclusion criteria have made it difficult to estab-
lish diagnostic markers for the disease.
A consensus definition of “bladder pain syndrome/
interstitial cystitis (BPS/IC)” was proposed by the European
Society for the Study of Interstitial Cystitis (ESSIC). The
diagnosis is based on chronic pelvic pain, pressure or discom-
fort perceived to be related to the urinary symptom accompa-
nied by at least one other urinary symptom such as persistent
urge to void or frequency [4]. Confusable diseases [i.e. carci-
noma, infection, overactive bladder (OAB)] need to be exclud-
ed. The severity of BPS/IC is classified by the rating of
cystoscopic and histopathological evidence [4]. The maximum
cystoscopic severity is the finding of Hunner’s lesions, and the
maximum histopathological severity is the finding of inflam-
matory infiltrates and/or detrusor mastocytosis and/or granula-
tion tissue and/or intrafascicular fibrosis. These maximum
findings are referred to as “ESSIC type 3C” [4].
In an effort to more precisely define suitable BPS/IC
diagnostic markers, our research team conducted a pilot
study in 2009 comparing gene expression analysis
(Affymetrix GeneChip® Human Genome U133 Plus 2.0)
of bladder biopsies from five patients with BPS/IC ESSIC
type 3C and six healthy controls [5]. Approximately 1,000
genes from more than 50,000 probe sets were found to have
a BPS/IC to healthy expression ratio greater than two. The
corresponding gene expression patterns were characteristic
for immune system diseases, and they predicted chronic
inflammation with B- and T-lymphocyte infiltration. In ad-
dition, the array data suggest an abnormal differentiation of
the urothelium which is in agreement with earlier results
[6–8]. Two urothelium-specific genes, cytokeratin 20
(KRT20) and uroplakin 1B (UPK1B), were found to be
expressed at very low levels [5].
While gene expression arrays can provide a large amount
of information, the process is expensive, time-consuming and
requires specialized equipment. We investigated if it was
possible to characterize Hunner’s positive BPS/IC by the
quantification of seven representative urothelial, B- and T-
cell markers. We hypothesized that a local B-cell activation
would lead to high levels of antibody concentration in urine.
Materials and methods
Description of patients
This prospective cohort study assigned patients recruited at
one urogynaecological centre in Switzerland from 2006 to
2011 to three comparison groups: BPS/IC ESSIC type 3C
(group 1, n=15), OAB (group 2, n=11) and healthy controls
(group 3, n=8). Each woman reviewed and completed rel-
evant study documentation approved by the local ethics
commission including an informed consent form (reference
9900.013).
In order to detect markers, homogeneous groups of
patients were required. Consequently, patients with pre-
dominant pain symptoms were selected based on their
diagnosis with classic ulcerative IC or IC with Hunner’s
lesions that conformed to the BPS/IC ESSIC type 3C
criteria [4]. “Hunner’s lesions” were identified according
to ESSIC [4] as distinctive, circumscript reddened muco-
sal areas with small vessels radiating towards a central
scar that, upon bladder distension, will rupture and bleed.
As a control group, we chose patients who had primary
urgency symptoms and a cystoscopically non-inflamed
bladder wall (“non-inflammatory OAB”). These patients
represent a subgroup of the OAB condition since there
are also reports of an association between OAB and
inflammation [9–11]. Healthy control patients were iden-
tified as women with no bladder symptoms and who
were hospitalized for a hysterectomy shortly before en-
rolment in the study. Patients with urinary tract infections
were excluded.
Biopsy removal and real-time quantitative polymerase chain
reaction (RT-qPCR)
Two cold-cup biopsies were taken from each patient and,
when present, from the transition zone lesion/non-lesion.
Thus, bladder biopsies included various amounts of
urothelium, submucosa and muscularis propria (detrusor).
Histopathological testing of one of these tissue samples
included mast cell quantification. Detrusor mastocytosis
was defined according to ESSIC [4] as mast cell counts
greater than 28 mast cells/mm2. The other biopsied tissue
was preserved in RNAlater (76104, QIAGEN, Valencia,
CA, USA) and used for RNA isolation and quantifica-
tion as described in the report of our pilot study [5].
Reverse transcription and RT-qPCR were done with
materials and equipment from Applied Biosystems
(Life Technologies, Zug, Switzerland) as follows:
TaqMan® Reverse Transcription Reagents (N8080234)
for reverse transcription, inventoried Human TaqMan®
Gene Expression Assays (4331182) and TaqMan®
Universal PCR Master Mix (4364340) for RT-qPCR on
an Applied Biosystems 7500 Real-Time PCR System.
The following TaqMan® Gene Expression Assays
(4331182) were analysed: cytotoxic T-lymphocyte-
associated protein 4 (CTLA4, Hs03044418_m1) as a T-
cell marker; CD20 (membrane-spanning 4-domains, sub-
family A, member 1 MS4A1, Hs00544819_m1) and
2050 Int Urogynecol J (2013) 24:2049–2057
CD79A molecule, immunoglobulin-associated alpha
(CD79A, Hs00233566_m1) as B-cell markers; immuno-
globulin heavy locus (IGH@, Hs00378230_g1) as a
marker for antibody heavy chain gene expression; and
uroplakin 1B (UPK1B, Hs00199583_m1), uroplakin 3A
(UPK3A, Hs00199590_m1) and cytokeratin 20 (KRT20,
Hs00300643_m1) as urothelial markers. RT-qPCR reac-
tions were done in duplicates in a 25 μl volume.
Standard cycling conditions were used (2 min 50 °C,
10 min 95 °C, 40 cycles 15 s 95 °C/1 min 60 °C).
Relative gene expression (comparative Ct method quan-
titation) was calculated with the 7500 System SDS
software version 1.3. Results were given as “relative
expression” using glyceraldehyde-3-phosphate dehydro-
genase (GAPDH, Hs99999905_m1) as the endogenous
control and healthy control patient 005 [5] as the
calibrator.
Immunohistochemistry
As described in our previous study, biopsied tissue was
embedded in paraffin and sections were stained with
either haematoxylin and eosin or Giemsa and van
Gieson elastin [5]. For immunohistochemistry testing,
biopsy sections were treated according to the standard
protocol with the Leica BOND-MAX automated system
using Leica Novocastra reagents (Biosystems, Nunningen,
Switzerland). The standard protocol for immunohisto-
chemistry was as follows: Dewaxing (AR9222), Epitope
Retrieval Solution 2 (AR9640) and Bond Polymer Refine
Detection Kit (DS9800) or Bond Polymer Refine Red
Detection Kit (DS9390). The primary antibodies were
1F6 mouse monoclonal antibody to cluster of differenti-
ation 4 (CD4, NCL-CD4-1F6, Novocastra) diluted 1:50;
MJ1 mouse monoclonal antibody to CD20 (NCL-CD20-
MJ1, Novocastra) diluted 1:100; 11E3 mouse monoclonal
antibody to CD79A (NCL-CD79a-225, Novocastra) dilut-
ed 1:125; AU-1 mouse monoclonal antibody to uroplakin
3 (UPK3, 345 M-14, Cell Marque, Rocklin, CA, USA)
diluted 1:25; and PW31 mouse monoclonal antibody to
KRT20 (NCL-L-CK20-561, Novocastra) diluted 1:200.
Microphotographs were taken at ×20 magnification with a
UC30 colour camera mounted on a BX43 Olympus System
Microscope. Images were processed by the CellF image anal-
ysis software (Olympus, Volketswil, Switzerland).
Blood handling and quantification of plasma IgG and IgA
Blood was collected in VACUETTE® Heparin tubes
(Greiner Bio-One, St. Gallen, Switzerland) one day before
biopsy. IgG and IgA concentrations were determined on a
cobas® 6000 analyzer (Roche Diagnostics AG, Rotkreuz,
Switzerland).
Urine handling and quantification of urinary
immunoglobulins
Urine was obtained through urinary catheterization one day
before the biopsy. Standard laboratory techniques included a
routine urine status and a urine culture. Sterile urine was
immediately centrifuged (5 min, 900 g), and the supernatant
was frozen at −20 °C and subsequently stored at −80 °C.
After thawing, protease inhibitor (Complete 04693116001,
Roche Diagnostics AG, Rotkreuz, Switzerland) was added
and 300 μl-aliquots were stored at −80 °C. Concentration of
urine creatinine was determined with the CREA plus kit
from Roche/Hitachi on a Roche/Hitachi Modular System P
Chemistry Analyzer (Roche Diagnostics AG, Rotkreuz,
Switzerland) at Ilamed AG, Institute for Laboratory
Medicine (Frauenfeld, Switzerland). For immunoglobulin
quantification, urine aliquots were thawed and centrifuged
for 15 min at 2,000 g. Supernatants were adjusted to pH 7.4
by adding a modified phosphate-buffered saline (PBS) buff-
er (final 1× concentration: 137 mM NaCl, 2.7 mM KCl,
40 mM phosphate buffer, pH 7.4). To quantify the protein
concentration, three different dilutions were measured per
urine sample. IgG and IgA concentrations were determined
on a BD FACSCalibur flow cytometry instrument using
Human Total IgG CBA Flex Set (No. 558679) and Human
Total IgA CBA Flex Set (No. 558681) kits in accordance
with the manufacturer’s protocol (BD Biosciences,
Allschwil, Switzerland).
Statistics
Statistical analyses were done in IBM® SPSS® Statistics
(version 19). A p value of less than 0.05 was considered to
indicate statistical significance. Tests of normality (Shapiro-
Wilk) and homogeneity of variance (Levene statistic) were
done with all continuous variables. The Kruskal-Wallis test
was used for non-parametric data. Post hoc tests (Mann-
Whitney U) identified differences between two groups, and
the Bonferroni correction was applied. As such, a p value of
0.016 (0.05/3) indicated significance. For normally distrib-
uted data, analysis of variance (ANOVA) followed by
Tukey’s HSD post hoc tests were used to detect differences
between the groups. Non-parametric receiver-operating
characteristic (ROC) curves were generated for all bio-
markers to plot the sensitivity against the false-positive rate
(1-specificity). To accomplish this, biomarker values for
BPS/IC ESSIC type 3C were compared to values of OAB
combined with the healthy control group. The optimal cut-
off for each biomarker was selected to maximize the sum of
sensitivity and specificity [Youden index = max. (selectivity +
specificity-1] [12]. The accuracy of a biomarker to predict
BPS/IC, defined as the average of sensitivity and specificity,
was also calculated.
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Results
A total of 140 women were assessed for enrolment in the
study; 106 were excluded from the analysis due to Hunner’s
negative forms of BPS/IC, an acute urinary tract infection or
incomplete/insufficient tissue/urine samples or missing
medical data. The 34 eligible women were grouped as
follows: 15 in the BPS/IC ESSIC type 3C group, 11 in the
OAB group and 8 in the control group. Demographic data of
the study population are summarized in Table 1.
High expression of B- and T-cell-specific genes and low
expression of urothelium-specific genes in bladder biopsies
of patients with BPS/IC ESSIC type 3C
For the BPS/IC ESSIC type 3C group, the statistical evalu-
ation of the RT-qPCR data showed significantly high ex-
pression of the T- and B-cell-specific genes CTLA4, CD20,
CD79A and IGH@ and significantly low expression of the
urothelium-specific genes UPK1B, UPK3A and KRT20
(Table 2) when compared with the other study groups. All
seven gene expressions were relatively accurate biomarkers
for BPS/IC ESSIC type 3C (Table 3).
Abnormal urothelial gene expression in women with OAB
In the OAB group, the expression of the B- and T-cell-
specific genes was low, which was similar to, but slightly
above, the healthy control group (Table 2). The urothelial
markers were in intermediate ranges between the other two
groups, and the uroplakin gene UPK1B reached significant-
ly lower expression when compared to healthy controls
(Table 2).
Formation of reactive lymphocyte aggregates in patients
with BPS/IC ESSIC type 3C
To compare the gene expression data with characteristics at
the cellular level, paraffin sections were analysed by immu-
nohistochemistry. B-cells were stained by the CD79A mark-
er. T-helper cells that promote the adaptive immune
response and B-cell activation were highlighted by the
CD4 marker. Of 15 BPS/IC ESSIC type 3C patients, 13
had dense lymphocyte infiltrates in the bladder submucosa
with preferential perivascular location. B-lymphocytes were
found in the centre of the follicular aggregates and were
surrounded by T-lymphocytes (Fig. 1). In contrast, the other
two patient groups showed very limited lymphocyte infil-
tration with only occasional B- and T-cells in the submuco-
sa. In the urothelium, CD4-positive cells were clearly
elevated in the BPS/IC group as compared to the other
groups, whereas CD79A-positive cells were scarce in all
groups. Results similar to CD79A were observed for CD20
staining (data not shown).
Abnormal urothelial staining in BPS/IC ESSIC type 3C
patients
Biopsy sections of healthy controls were characterized by a
strong UPK3 staining with an enhancement in the umbrella
cells facing the bladder lumen (Fig. 2). Approximately 60 %
of the umbrella cells also stained positive for KRT20
(Fig. 2). On the contrary, the urothelium of BPS/IC ESSIC
type 3C patients was abnormal. In some cases it was thin,
scarcely present or even absent, and there were instances in
which it was lost during preparation because it did not
adhere well to the submucosa (Fig. 2). KRT20 staining









p value Post hoc test p<0.05
Subjects White 15 11 8 NA
Age Mean 66 (±11) 51 (±20) 47 (±10) p=0.006 Gr. 1&2 (p=0.035) S
Gr. 1&3 (p=0.011) S
Gr. 2&3 (p=0.773) NS
BMI Median 26 (range 22–34) 29 (range 19–43) 22 (range 20–27) p=0.236
Parity Median 3 (range 0–4) 2 (range 0–5) 2 (range 0–3) p=0.157
Smokers Smokers 1 (7 %) 2 (18 %) 1 (13 %) p=0.673
Urge incontinence Yes 5 7 1 p=0.067
Urge incontinence Several times a day 0 5 0 p=0.002 Gr. 1&2 (p=0.007) S
Gr. 1&3 (p=0.999) NS
Gr. 2&3 (p=0.045) S
Urge incontinence Occasionally 5 2 1 p=0.592
Gr. group, NA not applicable, S significant, NS not significant, BMI body mass index
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was absent in all of the 13 investigated BPS/IC ESSIC type
3C patients, and UPK3 staining was absent or weak without
the characteristic umbrella cell staining (in 13 of 14 inves-
tigated patients). In the OAB group, the urothelium was
clearly present and KRT20 staining was comparable to the
healthy controls; however, in six of ten patients the UPK3
staining was less intense (Fig. 2).
High levels of urinary immunoglobulins in women
with BPS/IC ESSIC type 3C
The obvious accumulation of CD79A- and CD20-positive B-
cells indicated a local immune response in the BPS/IC ESSIC
type 3C group. The quantification of secretory IgA and IgG
showed a significantly high level of these immunoglobulins in
Table 2 Statistics for gene expression (RT-qPCR)
Variable Descriptive
statistics






p value Post hoc test Bonferroni
correction
(p<0.016)
CD79A_qPCR Mean 11.16 0.36 0.29 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 9.17 0.56 0.47 Gr. 1&3 (p<0.0001) S
Median 8.94 0.12 0.06 Gr. 2&3 (p=0.215) NS
Minimum 1.30 0.02 0.01
Maximum 40.90 1.96 1.22
CD20_qPCR Mean 14.11 0.71 0.21 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 9.71 1.72 0.46 Gr. 1&3 (p<0.0001) S
Median 13.58 0.16 0.01 Gr. 2&3 (p=0.240) NS
Minimum 1.50 0.00 0.00
Maximum 33.78 5.85 1.31
CTLA4_qPCR Mean 13.62 0.78 0.53 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 10.77 0.55 0.51 Gr. 1&3 (p<0.0001) S
Median 10.13 0.57 0.25 Gr. 2&3 (p=0.107) NS
Minimum 2.39 0.28 0.14
Maximum 35.67 1.95 1.55
IGH@_qPCR Mean 44.11 0.75 1.01 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 53.58 0.91 1.83 Gr. 1&3 (p<0.0001) S
Median 23.71 0.33 0.22 Gr. 2&3 (p=0.563) NS
Minimum 1.30 0.01 0.00
Maximum 158.19 2.79 5.28
KRT20_qPCR Mean 0.22 1.84 2.31 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 0.63 1.97 1.69 Gr. 1&3 (p<0.0001) S
Median 0.00 1.02 2.13 Gr. 2&3 (p=0.283) NS
Minimum 0.00 0.22 0.27
Maximum 2.32 6.69 5.78
UPK1B_qPCR Mean 0.13 0.87 1.37 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 0.18 0.41 0.32 Gr. 1&3 (p<0.0001) S
Median 0.03 0.69 1.44 Gr. 2&3(p=0.013) S
Minimum 0.00 0.27 0.80
Maximum 0.65 1.52 1.78
UPK3A_qPCR Mean 0.13 1.02 1.97 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 0.30 0.64 0.81 Gr. 1&3 (p<0.0001) S
Median 0.03 1.02 2.13 Gr. 2&3 (p=0.021) NS
Minimum 0.00 0.28 0.73
Maximum 1.13 2.50 3.27
Gr. group, S significant, NS not significant
a Relative gene expression
bσ: standard deviation
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the urine (Table 4). This was not the case for the other two
study groups, although values for OAB were above healthy
control levels. Blood IgA and IgG levels were not significant-
ly different for the three study groups (data not shown). Both
urinary IgA and IgG were relatively accurate biomarkers for
BPS/IC ESSIC type 3C (Table 3).
Elevated number of mast cells in detrusor muscle
All patients with BPS/IC ESSIC type 3C had elevated mast
cell counts in the detrusor which was associated with high
B- and T-cell marker expression. However, this association
was not found in the other groups. While the B- and T-cell
marker expression was low for both groups, 3 of 11 OAB
patients and 4 of 8 healthy controls had elevated mast cell
counts in the detrusor.
Discussion
Gene expression analysis of four T- and B-cell markers
(CTLA4, CD20, CD79A and IGH@) and three urothelial











CD79A 1.26 0.99 (0.99–1.00) 0.95 0.97 1 0.95 0.94 1
CD20 1.41 0.98 (0.95–1.00) 0.95 0.97 1 0.95 0.94 1
CTLA4 2.17 1.00 (1.00–1.00) 1 1 1 1 1 1
IGH@ 2.23 0.97 (0.93–1.00) 0.83 0.91 0.93 0.89 0.88 0.94
KRT20 0.13 0.94 (0.84–1.00) 0.87 0.93 0.87 1 1 0.95
UPK1B 0.43 0.98 (0.94–1.00) 0.88 0.94 0.93 0.95 0.93 0.95
UPK3A 0.44 0.95 (0.88–1.00) 0.83 0.91 0.93 0.89 0.88 0.94
IgA 194.36 0.97 (0.91–1.00) 0.83 0.91 0.93 0.89 0.88 0.94
IgG 246.17 0.96 (0.89–1.00) 0.89 0.95 1 0.89 0.88 1
AUROC area under ROC curve, CI confidence interval
aCD79A, CD20, CTLA4, IGH@, KRT20, UPK1B, UPK3A: RT-qPCR (bladder biopsies)
b IgA and IgG: enzyme-linked immunosorbent assay quantification (urine)





Healthy ControlUlcerative IC OAB
Fig. 1 B- and T-lymphocyte staining in bladder submucosa. Immuno-
histochemistry with paraffin sections of bladder biopsies using primary
monoclonal antibodies against CD4 (T-cell marker) and CD79A (B-
cell marker). Representative pictures are shown for the three investi-
gated groups, BPS/IC ESSIC type 3C (group 1), OAB (group 2) and
healthy controls (group 3). The respective CD79A and CD4 stainings
are from the same biopsy location. All pictures are at the same mag-
nification. The lymphocyte aggregate shown has a size of 100 μm×
170 μm and lymphocyte counts of approximately 200 cells; this results
in a lymphocyte density of 1.2×104 cells/mm2
2054 Int Urogynecol J (2013) 24:2049–2057
markers (UPK1B, UPK3A and KRT20) revealed significant
differences between the BPS/IC ESSIC type 3C group and
the two control groups. High concentrations of IgG and IgA
in urine, but not in blood, were associated with high expres-
sion of lymphocyte-specific genes and follicular B- and T-
cell aggregates in the submucosa and were consistent with
our hypothesis that there is a local immune response with B-
cell activation in cases of BPS/IC ESSIC type 3C. In addition,
urothelium-specific gene expressions were low in BPS/IC
ESSIC type 3C. One urothelial marker (UPK1B) even reached
significantly lower expression for non-inflammatory OAB
when compared to the healthy control group. For most other
gene expression markers and the urine immunoglobulin con-
centrations, the OAB values lie between those of the healthy
control group and the severe BPS/IC form.
The results for BPS/IC ESSIC type 3C are consistent
with earlier findings that describe severe inflammatory in-
filtrates and an abnormal urothelium for this disease subtype
[1, 2, 6–8, 13–16]. In contrast to previous studies, though,




Fig. 2 Staining of urothelium-specific proteins in bladder biopsies.
Immunohistochemistry with paraffin sections of bladder biopsies using
primary monoclonal antibodies against two urothelial markers, UPK3
(uroplakin 3) and KRT20 (cytokeratin 20). Representative pictures are
shown for the three investigated groups, BPS/IC ESSIC type 3C
(group 1), OAB (group 2) and healthy controls (group 3). The respec-
tive UPK3 and KRT20 stainings are from the same biopsy location. All
pictures are at the same magnification
Table 4 Statistics for immunoglobulin concentration in urine
Variable Descriptive
statistics






p value Post hoc test Bonferroni correction
(p<0.016)
IgA Mean 693 150 92 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 530 57 56 Gr. 1&3 (p<0.0001) S
Median 518 141 78 Gr. 2&3 (p=0.058) NS
Minimum 136 69 27
Maximum 1,781 251 192
IgG Mean 1,317 213 115 p<0.0001 Gr. 1&2 (p<0.0001) S
σb 1,466 285 75 Gr. 1&3 (p<0.0001) S
Median 672 98 115 Gr. 2&3 (p=0.741) NS
Minimum 253 33 17
Maximum 5,909 999 239
Gr. group, S significant, NS not significant
a ng immunoglobulin/μmol creatinine
bσ: standard deviation
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markers for both the inflammatory and the urothelial aspects
of the disease. Measurement of these markers may aid in the
detection of BPS/IC ESSIC type 3C.
Although urinary immunoglobulins have been detected
in earlier studies [17], this is the first report on BPS/IC
ESSIC type 3C to show significantly high levels of anti-
bodies in urine.
OAB and BPS/IC are regarded as different syndromes—
urgency is considered the hallmark symptom of OAB and
pain is the hallmark symptom of BPS/IC [18]. In our study,
OAB patients with non-inflammatory cystoscopic findings
served as a control group. Our intention was to determine if
the marker values for the OAB group were more similar to
those of the BPS/IC group, the healthy group, or if the values
were at intermediate ranges between these two groups since
other recently published studies found an overlap between
OAB and BPS/IC on both a clinical and diagnostic level
[9–11, 18]. Under this assumption, the results we obtained
for the OAB group can be explained.
The low expression of the urothelial genes in BPS/IC type
3C might be due to a loss of urothelium within the Hunner’s
lesion, which has also been described by other researchers [19,
20]. However, in our previous study [5], two biopsies of a
Hunner’s positive BPS/IC bladder were analysed—one from
the transition zone Hunner’s lesion/non-lesion and the second
from a normal-looking area of the bladder. The urothelial
genes UPK1B (210064_s_at) and KRT20 (213953_at) were
shown to be expressed at significantly lower levels, even in
the non-affected, normal-looking bladder tissue [5].
Only a few studies addressed the impact of urothelium
integrity on OAB; however, Liu et al. [10] recently found
that the urothelial barrier function was normal in OAB
patients. Conversely, findings from our study showed sig-
nificantly low expression of one urothelial marker (UPK1B)
in non-inflammatory OAB patients compared to the healthy
control group. Limited comparisons can be made between
these two studies since Liu et al. used patients with stress
urinary incontinence as controls rather than patients free of
bladder symptoms. Moreover, they performed integrated
image sections measuring immunofluorescence rather than
comprehensive quantitative gene expressions, and they
looked at different urothelial markers (zonula occludens-1
and E-cadherin rather than UPK1B, UPK3A and KRT20).
Even though efforts have been made [13, 21], there are
currently no commonly accepted markers to diagnose
BPS/IC. Furthermore, there are only invasive techniques to
differentiate Hunner’s positive from Hunner’s negative
BPS/IC. It is likely that the IgA and IgG urine findings are
due to the presence of lymphocyte infiltrates in the submu-
cosa and would not be elevated if the histology were normal.
As part of our future research, we plan to investigate wheth-
er elevated urinary IgA and IgG levels are indicative of
Hunner’s lesion, which would mean a non-invasive
technique to identify this disease subtype would be avail-
able. Since an association between BPS/IC and autoimmune
diseases has been suggested [22], determining the specific-
ity of the urinary immunoglobulins would likely give new
information on the catalyst and the pathophysiology of this
local immune reaction.
The B-cell markers CD79A and CD20 are similarly
expressed (Table 2); therefore, quantification of one of these
representative markers should be sufficient. The elevated
number of B-cells in the bladder wall is an important con-
sideration for prospective therapeutic approaches to BPS/IC
ESSIC type 3C. Rituximab, a monoclonal antibody specific
for CD20, selectively destroys B-cells [23]. Given our find-
ings of high CD20 expression in Hunner’s positive BPS/IC,
we would propose treatment with rituximab, a treatment
which currently is approved for use with non-Hodgkin’s
lymphoma, rheumatoid arthritis and ANCA (anti-neutrophil
cytoplasmic antibodies)-associated vasculitis [23, 24]. By
tracking changes in gene expression, we may be able to
quantify and monitor therapy progress and outcomes.
With regard to study limitations, the low number of study
participants was largely a consequence of a small pool of
eligible patients at one recruitment centre and a relatively
rare condition. Furthermore, the healthy controls were pa-
tients hospitalized for gynaecological surgery and
underwent cystoscopy and bladder biopsy solely for study
purposes. For this reason, patient groups could not be
matched by age, which could signify a potential source of
bias. Similar to other studies [25, 26], patients with
Hunner’s lesions were older than the comparison groups.
We chose to exclude patients with Hunner’s negative
BPS/IC since they make up a large and heterogeneous
group. This study was intended as an initial investigative
step to find biomarkers; therefore, we focused our research
efforts on the small homogeneous group of patients with
Hunner’s positive BPS/IC who could easily be identified
with cystoscopy. For future studies, a careful subdivision of
the heterogeneous Hunner’s negative BPS/IC group based
on the ESSIC grading system (i.e. cystoscopy and biopsy
data) would be required.
Tests of sensitivity and specificity showed that all
markers were accurate biomarkers for BPS/IC ESSIC type
3C (Table 3). However, these results were obtained from
small, homogeneous subgroups of patients. Further analyses
are planned with a larger cohort of patients, including those
with Hunner’s negative BPS/IC.
In summary, this study identified seven quantifiable gene
expression markers which can describe the current stage of
the clinically defined subtype of BPS/IC ESSIC type 3C.
Objective, measurable results can be generated within 2 days
and more focused monitoring of therapy outcomes could be
carried out. Further research is needed to develop more
effective strategies for treating Hunner’s positive BPS/IC,
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such as targeted therapy with monoclonal antibodies against
B-cells. Detection of elevated urinary IgA and IgG levels
could be a non-invasive technique to diagnose the subtype
BPS/IC ESSIC type 3C representing ∼10 % of all BPS/IC
patients [20]. Lastly, since the results for the non-inflammatory
OAB group were in intermediate ranges between BPS/IC
ESSIC type 3C and the healthy control groups, future research
efforts ought to assess if BPS/IC and OAB are related.
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